91 results on '"Kolb, Brigitte"'
Search Results
52. Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)
53. Bendamustine, Bortezomib and Dexamethasone (BVD) In Elderly Patients With Multiple Myeloma In First Relapse: Final Analysis Of The Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial
54. The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma
55. Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience
56. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.
57. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
58. Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods
59. Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial
60. Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience
61. Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study
62. Prolonged Overall Survival with Pomalidomide and Dexamethasone in Myeloma Characterized with End Stage Disease.
63. The Combination of ISS 3, High LDH and t(4;14) and/or Del(17p) Identify a Simple Prognostic Index for Overall Survival in Patients Treated with Novel Agents-Based Induction Therapy and Front-Line Autologous Stem Cell Transplantation, and Allow the Definition of a Subgroup of Patients At High-Risk of Early Death From Progressive Disease
64. An aggressive B-cell lymphoma with rearrangements ofMYCandCCND1genes: a rare subtype of double-hit lymphoma
65. Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
66. Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
67. Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol.
68. Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.
69. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
70. Incidence and Prognostic Value of Chromosomal Abnormalities in Elderly Patients with myeloma: The IFM Experience on 1095 Patients
71. Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial
72. Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02
73. Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
74. Effectiveness of Second Line Treatment in AL Amyloidosis Patients Refractory to M-Dex.
75. Bortezomib, Doxorubicin and Dexamethasone (PAD) Prior to High-Dose Melphalan / Autologous Stem Cell Transplantation for Newly Diagnosed Plasma Cell Dycrasias.
76. Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs?
77. Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.
78. Preliminary Results of a Prospective Randomized Study Comparing First Line Conventional Therapy Versus High Dose Therapy with Autologous CD34+ Purified Progenitor Cell Support in B CLL Patients with B and C Binet Stages: The GOELAMS LLC98 Study.
79. ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases.
80. An aggressive B-cell lymphoma with rearrangements of MYC and CCND1 genes: a rare subtype of double-hit lymphoma.
81. High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02
82. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
83. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
84. Bortezomib(Velcade (R))-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation
85. Susceptibility of malignant and normal target cells to the cytotoxic action of bone-marrow macrophages activated in vitro with the macrophage cytotoxicity factor (MCF)
86. Crizotinib in Advanced ALK+ Anaplastic Large Cell Lymphoma in Children and Adults: Results of the Acs© Phase II Trial
87. Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation
88. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
89. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
90. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
91. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.